I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on January 23, 2009.

ELECTION UNDER 35 U.S.C. § 121 Patent Application
Docket No. SER.100X

Frank C. Eisenschenk, Ph.D., Patent Attorney

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Aditi Dutt

Art Unit

1649

Applicants

Christopher Hug, Harvey F. Lodish

Serial No.

10/553,430

Filed

October 18, 2005

Conf. No.

3770

For

Use of T-Cadherin as a Target

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

## ELECTION UNDER 35 U.S.C. § 121 AND SUPPLEMENTAL PRELIMINARY AMENDMENT

Sir:

In response to the written Restriction Requirement dated December 23, 2008 in the above-identified patent application, Applicants hereby elect to prosecute the invention of Group V (claims 59-64), without traverse. As the species, Applicants hereby elect metabolic disorders. As the metabolic disorder, Applicants hereby elect obesity. As the candidate modulator, Applicants hereby elect soluble form of T-cadherin.

Prior to examination, Applicants respectfully request that the subject application be amended as follows: